Trials / Completed
CompletedNCT00788528
Open-Label Extension (OLE) Study for Safety and Efficacy of Velneperit (S-2367) in Obese Subjects
Open-Label Extension (OLE) Safety and Efficacy Study of Velneperit (S-2367) Following the Year-Long Controlled Clinical Trials of S-2367 in Obese Males and Females
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 766 (actual)
- Sponsor
- Shionogi · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this open-label extension study is to evaluate the safety and efficacy of velneperit (S-2367) in obese subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | S-2367 (velneperit) | Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks |
Timeline
- Start date
- 2008-08-01
- Primary completion
- 2010-02-01
- Completion
- 2010-03-01
- First posted
- 2008-11-11
- Last updated
- 2018-05-01
Locations
73 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00788528. Inclusion in this directory is not an endorsement.